WHITE, STEVEN K.,IVANISEVIC, IGOR,STEPHENS, KYLE,ANDRES, MARK,WOLF, BRENTON
申请号：
CA2728889
公开号：
CA2728889C
申请日:
2009.04.03
申请国别(地区):
CA
年份:
2016
代理人:
摘要：
The invention provides and describes solid state 17.alpha.-ethynyl-androst- 5-ene-3.beta.,7.beta.,17.beta.-triol including amorphousand crystalline forms and specific polymorphic forms thereof. Anhydrates andsolvates of 17.alpha.-ethynyl-androst-5- ene-3.beta.,7.beta.,17.beta.-triolinclude Form I anhydrate and Form IV and Form V solvates. The inventionfurther relates to solid and suspension formulationscontaining 17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol in adescribed solid state form and use of the formulations to treathyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, andautoimmune conditions, such as rheumatoid arthritis,ulcerative colitis and type 1 diabetes, among other inflammation relatedconditions in subjects or human patients. The inventionalso relates to methods to make liquid formulations from solid state forms of17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol anduses of such formulations in treating the described conditions.
